Medvi faces federal probes and a class-action lawsuit after its rise as a two-man AI unicorn. The firm claims it reached a $1.8 billion valuation with a skeleton crew. Court records and FDA letters now challenge that narrative. Compliance gaps look like the real driver of the growth.
- Medvi faces federal investigations and a class-action lawsuit challenging its $1.8 billion valuation and AI-driven growth model.
- The FDA issued Warning Letter #721455 on Feb. 20 after Medvi reported a 16.2% net profit margin on $401 million revenue.
- A data breach at partner OpenLoop Health leaked 1.6 million records, exposing Medvi customers to dark web identity theft risks.
FDA Letter Attacked Medvi’s Drug Branding
The FDA sent Warning Letter #721455 to Medvi on Feb. 20. Regulators accused the company of misbranding compounded GLP-1 drugs. Pictured pill bottles used “MEDVi” labels. Officials said this suggested internal production when Medvi actually used outside labs.
“The compounded semaglutide and tirzepatide products displayed on your website identify ‘MEDVi’ on the pictured label, suggesting MEDVi is the compounder of those drugs when in fact it is not,” the FDA wrote.
The letter also hit claims that the drugs matched approved brands like Ozempic. Medvi ignored its 15-day response deadline. No public records of a filing appeared in the weeks following the warning.
OpenLoop Security Failure Leaked Records
Partner network OpenLoop Health suffered a massive security breach in Jan. 2026. Intruders held access for 48 hours starting Jan. 7. A hacker called “Stuckin2019” claimed 1.6 million patient records reached the dark web. Texas officials confirmed 68,160 affected residents.
Genuine News Deserves Honest Attention.
High-conviction projects require an intelligent audience. Connect with readers who value sharp reporting.
👉 Submit Your PRThe leak exposed medical details and birth dates. OpenLoop offered credit monitoring to victims. Medvi customers’ data sat on these servers during the hit. The company relied on OpenLoop for patient management and doctor oversight. Medvi externalized its security risks to a partner that failed.
Lawsuit Alleged Nationwide Fraud Scheme
A class-action suit reached the Delaware federal court in Nov. 2025. The complaint alleged Medvi-affiliated groups ran a nationwide scheme for unapproved tirzepatide. The filing described identical websites using deceptive language.
Plaintiffs argued they bought drugs believing they received personalized supervision. The product was mass-produced medication sold at scale instead. The suit alleged a strategy to spread risk across multiple domains.
Analysts Hit Medvi’s Margin Claims
Medvi reported a 16.2% net profit margin in 2025 on $401 million in revenue. Rival Hims & Hers reached a 5.5% net margin on $2.4 billion. The gap totaled 10.7% points. Analysts questioned the efficiency narrative. They argued Medvi maintained margins by omitting guardrails like physician vetting.
The company attributed the numbers to AI and outsourcing. Medvi kept the ad spend and the customer relationship while moving legal risks to third parties. Analysts argued this model failed to protect the patient.
Chain Street’s Take
Medvi is a risk. Hype sold the narrative. Regulators found the gaps. Security failed the patients. Valuation outran the reality.
The FDA letter and the OpenLoop breach prove the costs were just hidden. Investors should look past the two-man headcount. Medicine requires safety and compliance. Medvi cut the corners to pump the numbers. The narrative is falling. Substance is finally catching up.
Activate Intelligence Layer
Institutional-grade structural analysis for this article.
